TY  - JOUR
AU  - Seger, Aline
AU  - Farrher, Ezequiel
AU  - Doppler, Christopher E. J.
AU  - Gogishvili, Ana
AU  - Worthoff, Wieland A.
AU  - Filss, Christian P.
AU  - Barbe, Michael T.
AU  - Holtbernd, Florian
AU  - Shah, N. Jon
AU  - Fink, Gereon R.
AU  - Sommerauer, Michael
TI  - Putaminal y ‐Aminobutyric Acid Modulates Motor Response to Dopaminergic Therapy in Parkinson's Disease
JO  - Movement disorders
VL  - 36
IS  - 9
SN  - 1531-8257
CY  - New York, NY
PB  - Wiley
M1  - FZJ-2021-02555
SP  - 2187-2192
PY  - 2021
AB  - BackgroundMotor response to dopaminergic therapy is a characteristic of patients with Parkinson's disease (PD). Whether nondopaminergic neurotransmitters contribute to treatment response is uncertain.ObjectivesThe aim of this study is to determine whether putaminal y-aminobutyric acid (GABA) levels are associated with dopaminergic motor response.MethodsWe assessed putaminal GABA levels in 19 PD patients and 13 healthy controls (HCs) utilizing ultra-high field proton magnetic resonance spectroscopy. Motor performance was evaluated using the Movement Disorder Society—Unified Parkinson's Disease Rating Scale, Part III, in the ON and OFF states. Statistical analysis comprised group comparisons, correlation analysis, and multiple linear regression.ResultsIn PD, GABA levels were significantly higher compared to HCs (1.50 ± 0.26 mM vs. 1.26 ± 0.31 mM, P = 0.022). Furthermore, GABA levels were independent predictors of absolute and relative dopaminergic treatment response.ConclusionsOur findings indicate that elevated putaminal GABA levels are associated with worse dopaminergic response in PD, emphasizing the essential role of nondopaminergic neurotransmitters in motor response. © 2021 The Authors. Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society
LB  - PUB:(DE-HGF)16
C6  - pmid:34096652
UR  - <Go to ISI:>//WOS:000658342200001
DO  - DOI:10.1002/mds.28674
UR  - https://juser.fz-juelich.de/record/893096
ER  -